Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.43
  • Today's Change-0.01 / -0.41%
  • Shares traded816.98k
  • 1 Year change-26.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Tilray Brands Inc have a median target of 3.25, with a high estimate of 3.55 and a low estimate of 2.94. The median estimate represents a 33.92% increase from the last price of 2.43.
High46.2%3.55
Med33.9%3.25
Low21.1%2.94

Earnings history & estimates in USD

On Jul 29, 2024, Tilray Brands Inc reported 4th quarter 2024 losses of -0.04 per share. This result was in line with the consensus of the 4 analysts following the company and exceeded last year's 4th quarter results by 73.33%.
The next earnings announcement is expected on Oct 02, 2024.
Average growth rate+14.64%
Tilray Brands Inc reported annual 2024 losses of -0.33 per share on Jul 29, 2024.
Average growth rate+85.96%
More ▼

Revenue history & estimates in USD

-32768 had 4th quarter 2024 revenues of 229.88m. This bettered the 227.30m consensus of the 9 analysts covering the company. This was 50.04% above the prior year's 4th quarter results.
Average growth rate+6.21%
-32768 had revenues for the full year 2024 of 788.94m. This was 25.80% above the prior year's results.
Average growth rate+12.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.